NeuroOne Medical TechnologiesNMTC
NMTC
About: NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Employees: 17
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
600% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 2
460% more capital invested
Capital invested by funds: $1.64M [Q1] → $9.18M (+$7.54M) [Q2]
67% more funds holding
Funds holding: 18 [Q1] → 30 (+12) [Q2]
20.91% more ownership
Funds ownership: 6.25% [Q1] → 27.16% (+20.91%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for NMTC.
Financial journalist opinion
Based on 6 articles about NMTC published over the past 30 days
Positive
Zacks Investment Research
6 days ago
NMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment
NeuroOne stock rallies after FDA clears its OneRF system, a minimally invasive solution targeting severe facial pain, scheduled to launch in late 2025.
Neutral
GlobeNewsWire
1 week ago
NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
FDA Clearance Further Validates Technology Platform and Offers Alternatives to Pharmaceutical and Invasive Surgical Treatments
Neutral
Seeking Alpha
1 week ago
NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call August 14, 2025 8:30 AM ET Company Participants David A. Rosa - President, CEO & Director Ronald W.
Neutral
GlobeNewsWire
1 week ago
NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%
Completed Oversubscribed $8.2 Million Capital Raise; Funded Through At Least Fiscal Year 2026 EDEN PRAIRIE, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the third quarter of fiscal year 2025 ended June 30, 2025.
Neutral
GlobeNewsWire
3 weeks ago
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update
EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025.
Neutral
GlobeNewsWire
3 weeks ago
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time
EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2025, before market open on August 14, 2025.
Neutral
GlobeNewsWire
1 month ago
NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office
Patent Strengthens Intellectual Property Portfolio Surrounding Neural Probe Technologies EDEN PRAIRIE, Minn., July 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has received a notice of allowance for a key patent from the U.S. Patent and Trademark Office (USPTO) titled, “Methods for Making Probe Devices and Related Devices”.
Neutral
GlobeNewsWire
2 months ago
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
Patient Treated with OneRF ® Ablation System Previously Experienced up to 10 Seizures a Day EDEN PRAIRIE, Minn., June 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that Clara—an early patient treated with the Company's patented OneRF® Ablation System—has successfully surpassed the one year milestone of being seizure free.
Neutral
GlobeNewsWire
2 months ago
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary
EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary.
Neutral
GlobeNewsWire
2 months ago
NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025
EDEN PRAIRIE, Minn., May 29, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the MedInvest MedTech, AI and Digital Health Conference taking place in San Francisco, CA on June 3-4, 2025.
Charts implemented using Lightweight Charts™